Acridine carboxamide explained

Acridine carboxamide is a chemotherapy agent that is being studied in the treatment of cancer. It belongs to the family of drugs called topoisomerase inhibitors.

While the agent was well tolerated in Phase II clinical trials, it did not show efficacy when tested against various types of cancers.^{[1] [2] [3] [4]}

See also

• Ondansetron, an isomer of Acridine carboxamide

Notes and References

1. Dittrich C, Dieras V, Kerbrat P, Punt C, Sorio R, Caponigro F, Paoletti X, de Balincourt C, Lacombe D, Fumoleau P . 19095200 . 6 . Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer . Investigational New Drugs . 21 . 3 . 347–52 . August 2003 . 14578683 . 10.1023/A:1025476813365 .
2. Caponigro F, Dittrich C, Sorensen JB, Schellens JH, Duffaud F, Paz Ares L, Lacombe D, de Balincourt C, Fumoleau P . 6 . Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer . European Journal of Cancer . 38 . 1 . 70–4 . January 2002 . 11750842 . 10.1016/S0959-8049(01)00336-7 .
3. Twelves C, Campone M, Coudert B, Van den Bent M, de Jonge M, Dittrich C, Rampling R, Sorio R, Lacombe D, de Balincourt C, Fumoleau P . 6 . Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme . Annals of Oncology . 13 . 5 . 777–80 . May 2002 . 12075748 . 10.1093/annonc/mdf121 . free .
4. Dittrich C, Coudert B, Paz-Ares L, Caponigro F, Salzberg M, Gamucci T, Paoletti X, Hermans C, Lacombe D, Fumoleau P . 6 . Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer . European Journal of Cancer . 39 . 3 . 330–4 . February 2003 . 12565985 . 10.1016/S0959-8049(02)00559-2 .